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We studied 459 consecutive patients with hematologic malignancies, median age 44 years (range, 15 to
71 years), who underwent transplantation with grafts from identical sibling donors (SIB; n ¼ 176), matched
unrelated donors (MUD; n ¼ 43), mismatched unrelated donors (mmUD; n ¼ 43), unrelated cord blood (UCB;
n ¼ 105) or HLA-haploidentical family donors (HAPLO; n ¼ 92). Graft-versus-host disease (GVHD) prophylaxis
consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD,
mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate
in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69%). Advanced disease phase
was more frequent, but not signiﬁcantly so, in the HAPLO and mmUD groups (P ¼ .08). Acute GVHD grade II-IV
was signiﬁcantly less frequent in the HAPLO, UCB, and MUD groups (14% to 21%) compared with the SIB (31%)
and mmUD (42%) groups (P < .001), and there was a trend toward less moderate-severe chronic GVHD in the
HAPLO and UCB groups (P ¼ .053). The proportion of patients off cyclosporine at 1 year ranged from 55% for
the SIB group to 81% for the HAPLO group (P < .001). Transplantation-related mortality at 2 years was lower in
the HAPLO and SIB groups (18% to 24%) compared with the MUD, mmUD, and UCB groups (33% to 35%;
P ¼ .10). Relapse rate was comparable in the 5 groups (P ¼ .80). The 4-year actuarial survival was 45% in the
SIB group, 43% in the MUD group, 40% in the mmUD group, 34% in the UCB group, and 52% in the HAPLO
group (P ¼ .10). In multivariate analysis, advanced disease was a negative predictor of survival (hazard ratio
[HR], 2.4; P < .0001), together with a diagnosis of acute leukemia (HR, 1.8; P ¼ .0001); HAPLO grafts were
comparable to SIB (P ¼ .80), whereas UCB had inferior survival (P ¼ .03). In conclusion, unmanipulated
haploidentical family donor transplants are an additional option for patients lacking a matched sibling donor.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
In the absence of a family matched donor for stem cell
transplantation, several alternative stem cell sources are
now available, including unrelated volunteer donors (UDs)
selected through the International Network of Registries [1],
single or double umbilical cord blood (UCB) units [2], or an
HLA-mismatched family donor, also referred to as haplo-
mismatched (HAPLO) [3]. For the latter, T cell depletion
(TCD) programs [4], CD34 selection [3], and, more recently,dgments on page 1578.
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14.05.029B cell depletion together with selective TCD [5] have been
used to prevent graft-versus-host disease (GVHD) with en-
couraging outcomes, comparable to those obtained with UCB
transplantation [6]. Problems with TCD or CD34-selected
HAPLO transplants are associated with the technology and
cost involved in graft manipulation and with slow immune
recovery, with a high incidence of infectious complications;
consequently, transplantation-related mortality (TRM) has
remained high [7]. The introduction of unmanipulated HAPLO
transplants some years ago has overcome the issues of tech-
nology and costs, with encouraging early results [8] that were
recently conﬁrmed [9].
In one of these programs, initiated in Baltimore [9], a
reduced-intensity conditioning (RIC) regimen, followed
by an unmanipulated HAPLO bone marrow transplant,Transplantation.
A.M. Raiola et al. / Biol Blood Marrow Transplant 20 (2014) 1573e15791574post-transplantation high-dose cyclophosphamide (PT-CY),
tacrolimus, andmycophenolate (MMF), resulted in a high rate
of stable engraftment, a low risk of graft versus host disease
(GVHD) [9]. We recently reported that a myeloablative con-
ditioning regimen followed by unmanipulated HAPLO trans-
plantation maintained the beneﬁcial low GVHD rate of PT-CY
and ensured a low rate of relapse in patients with active
disease at the time of transplantation [10]. We also have used
the nonmyeloablative program for patients with Hodgkin
disease undergoing HAPLO transplantation, and conﬁrmed
the results published by the Baltimore group [11,12].
In our collective practice, we have experience with all of
the different alternative donor types. In the present study,
we compared the outcomes of transplantation from HAPLO
donors with those of transplantation from matched UDs
(MUD), mismatched UDs (mmUD), single cord blood units
(UCB), and HLA-matched sibling donors (SIB) in the years
2006 to 2012.
PATIENTS AND METHODS
Patients
Eligible for this analysis were 459 patients with hematologic malig-
nancies undergoing a ﬁrst allogeneic transplantation at our center between
January 2006 and July 2012. The minimum follow-up for surviving patients
is at least 18 months. Clinical characteristics of the study group are sum-
marized in Table 1. The choice of donor was based on the availability of an
HLA-matched (8/8) or -mismatched (7/8) unrelated donor; the second
choice would have been a 5/6 or 4/6 UCB unit, and the third choice a HAPLO-
mismatched family donor. The expected delay to transplantation was taken
into account as well; a patient with active leukemia or lymphoma, would
not activate a donor search if it was thought that he or she could not wait
30 to 60 days to ﬁnd a suitable donor or a UCB unit, and a family HAPLO
transplantation was performed instead. Consequently, patients receiving
HAPLO grafts were more likely to have advanced disease at the time of
transplantation (Table 1). Owing to the short interval between determi-
nation of eligibility for transplantation and identiﬁcation of an available
HAPLO donor, the proportion of HAPLO grafts has increased signiﬁcantly in
recent years.
The median age of our patient population was 41 years (range 15 to
71 years), with approximately 40% of patients aged >50 years, with the
exception of UCB recipients (Table 1). The most common diagnosis was
acute leukemia (>40% of all cases; Table 1). The 215 patients with advanced
disease, deﬁned as second complete remission (CR2) or greater, included
193 patients with active disease and 22 in third complete remission (CR3).
European Group for Blood and Marrow Transplantation Score
The European Group for Blood and Marrow Transplantation (EBMT)
score incorporates disease phase (ﬁrst complete remission [CR1], CR2,
advanced), recipient age (0 to 20, 21 to 40, >40 years), donor-recipient sexTable 1
Clinical Characteristics by Donor Type (n ¼ 459 patients)
Characteristic SIB MUD
Number of patients 176 43
Age >50 yr, n (%) 72 (41) 15 (35)
Age, yr, median (range) 47 (15-69) 42 (19-66)
Advanced phase (>CR2), n (%) 77 (44) 18 (42)
Diagnosis
Acute leukemia, n (%) 85 (48) 19 (43)
Lymphoma, n 16 4
MPD, n 34 9
MDS, n 36 10
Other, n 5 1
EBMT score >2, n (%) 82 (46) 30 (70)
CMV serostatus /, n (%)y 9 (8) 8 (20)
Myeloablative regimen, n (%) 98 (55) 31 (72)
Stem cell source, n (%)
Bone marrow 156 (89) 26 (60)
Peripheral blood 20 (11) 17 (40)
UCB — —
* P < .05.
y CMV evaluable for serostatus evaluation, n ¼ 362.mismatch (female/male versus other), interval between diagnosis and
transplantation (</1 year), and donor type (SIB versus alternative) [13].
The proportion of patients with a high EBMT score (>2) was comparable in
the 3 groups of alternative donor transplant recipients (Table 1).HLA Matching
All SIB grafts were genotypically HLA matched; the 86 UD transplants
included 43 UD 8/8 (HLA-A, -B, -C, and -DRB1) matched (MUD) and 43 UD
<8/8 matched (mmUD). UCB units were 5/6 HLA-matched (n ¼ 54), 4/6
matched (n ¼ 48), or 3/6 matched (n ¼ 3). The 92 HAPLO grafts were all 3-4
HLA-A, -B, -C, -DRB1 antigen mismatched.Conditioning Regimens
Chemotherapy-based myeloablative conditioning regimens included
thiotepa (THIO), busulfan (BU), ﬂudarabine (FLU), referred to as TBF herein
[14,15] or BU-cyclophosphamide (CY). Regimens based on total body irra-
diation (TBI) included 9.9 to 12 Gy TBI in fractionated doses, with ﬂudarabine
(FLU-TBI) or cyclophosphamide (CY-TBI) [10]. Reduced-intensity conditioning
(RIC) regimens included FLU-CY-TBI 200 rads [11] and THIO-CY with or
without low-dose melphalan [16]. Both myeloablative and RIC regimens for
HAPLO transplantations have been described in detail previously [10,13].Stem Cell Source
The stem cell source was bone marrow in 302 patients, peripheral blood
in 52 patients, and UCB in 105 patients (Table 1). All grafts were unmanipu-
lated. The UCB units were all infused intrabone as described previously [17].GVHD Prophylaxis
Recipients of HLA-identical SIB grafts received cyclosporin A (CyA) þ
short-course metothrexate (MTX). Recipients of UD grafts received CyA þ
MTX þ antithymocyte globulin (ATG; Thymoglobulin; Sanoﬁ Aventis, France)
3.75 mg/kg on days 3 and 2 pretransplantation. UCB recipients received
CyA þ MMF and ATG [17]. Recipients of HAPLO grafts were given CyA from
day 0, MMF from day þ1, and CY 50 mg/kg on days þ3 and þ5 [10].Diagnosis and Treatment of GVHD
The clinical diagnosis of acute and chronic GVHDwas based on standard
criteria, and conﬁrmed by histological analysis of skin and/or rectal biopsy
specimens. First-line and second-line therapy for GVHD was provided ac-
cording to institutional protocols.Monitoring of Immune Reconstitution
Patients were monitored on day þ100 post-transplantation for immune
reconstitution, including serum immunoglobulin levels and lymphocyte
subpopulations. IgA serum levels and CD4þ cell counts were considered
indicative of immune recovery. All surviving patients had serum IgA avail-
able. One hundred ﬁfty-seven SIB recipients, 36 MUD recipients, 37 mmUD
recipients, 72 UCB recipients, and 76 HAPLO recipients were studied for CD4
recovery on day þ100.mmUD UCB HAPLO
43 105 92
15 (35) 24 (23) 36 (40)*
47 (17-62) 40 (18-64) 45 (17-69)
24 (56) 43 (41) 53 (58)*
19 (43) 70 (66) 39 (43)*
4 10 25
10 7 14
9 16 10
1 2 4
32 (74) 80 (76) 69 (75)*
4 (10) 8 (10) 5 (6)*
31 (72) 87 (83) 71 (77)*
28 (65) — 92 (100)*
15 (35) — —
— 105 (100) —
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Antimicrobial prophylaxis, started during administration of the con-
ditioning regimen, consisted of standard dose acyclovir, levoﬂoxacine
500 mg/day, and ﬂuconazole 400 mg/day until day þ75. Cytomegalovirus
(CMV) monitoring with pp65 antigenemia was started on day 7 and
continued twice-weekly until dayþ100; preemptive therapy (ganciclovir or
foscarnet) was given to patients positive for CMV antigenemia. Weekly
Epstein-Barr virus (EBV) monitoring by PCR was started on day þ15 and
continued weekly until day þ100: preemptive therapy with rituximab was
given to patients with a viral load >1000 copies/105 mononuclear cells.
Weekly monitoring of galactomannan was started on day 0 and continued
until day þ100, and positive patients received mould active antifungal
therapy.Statistical Analysis
The chi-square test and nonparametric unpaired test were used to
compare groups according to clinical characteristics; cumulative incidence
rates and survival were calculated. In calculating the cumulative incidence
of TRM, the competing risk was relapse; when calculating relapse, the
competing risk was TRM. Events for disease-free survival (DFS) were relapse
of the original disease or death, whichever occurred ﬁrst. The log-rank test
was used to univariately compare survival curves, and the Gray test was
used to univariately compare cumulative incidences.
Further multivariate Cox analysis on survival was run with patient and
disease variables and transplantation variables, including the 5 donor types
and intensity of the conditioning regimen. Variables with a P value <.15 in
univariate analysis were considered for the ﬁnal multivariate model. Simi-
larly, a multivariate Fine and Graymodel [18] were used to assess the impact
on cumulative incidence. The multivariate model was built following the
same rules as for the Cox model. For the Cox model, hazard ratios (HRs) are
reported, whereas for the Fine and Gray model, subhazard ratios (SHRs) are
shown. Stata version 11 (StataCorp, College Station, TX) and NCSS 7 (NCSS,
Kaysville, UT) were used for computation.RESULTS
Engraftment and Immune Reconstitution
The median time to a neutrophil count of >0.5  109/L
was 18 days in the SIB group, 17 days in the MUD group,
16 days in the mmUD group, 23 days in the UCB group, and
18 days in the HAPLO group (Table 2). Time to engraftment
was comparable in the SIB and all alternative donor groups
except UCB, which had signiﬁcantly slower neutrophil
engraftment (P < .001). Platelet recovery was signiﬁcantly
slower at all time points in the alternative donor groups
compared with the SIB group; day þ50 platelet counts were
160  109/L in the SIB group, 100  109/L in the MUD group,
110 109/L in themmUD group, 40 109/L in the UCB group,
and 118  109/L in the HAPLO group (P < .01). Lymphocyte
recovery was slower in the alternative donor graft recipients
in the ﬁrst month post-transplantation, and comparable
thereafter. The median day þ100 absolute circulating CD4þ
lymphocyte count was 229/mm3 in the SIB group, 106/mm3Table 2
Clinical Outcomes by Donor Type
Outcome SIB M
Number of patients 176 4
Days to engraftment, median (95% CI) 18 (10-26)
Days to acute GVHD, median (95% CI) 22 (5-95)
CD4 count on day þ100, median (95% CI) 229 (20-320) 1
IgA serum level on day þ100, mg/dL, median (95% CI) 58 (1-410)
Patients with infection on dayþ100, %
Bacterial 23 3
Fungal 4 1
CMV antigenemia 58 6
Patients off cyclosporin by day þ365, % 55 6
Follow-up days, median (95% CI) 730 (6-2840) 9
Engraftment was deﬁned as the ﬁrst day with a neutrophil count >0.5  109/L. Co
comparison group in all cases. Bacterial and fungal infections are expressed as the p
P < .05 level. CMV antigenemia is expressed as cumulative incidence; the overall
* P < .05.in the MUD group, 90/mm3 in the mmUD group, 63/mm3 in
the UCB group, and 190/mm3 in the HAPLO group. Compared
with SIB recipients, UCB recipients had signiﬁcantly lower
(P < .01) CD4 counts until 6 months post-transplantation.
UD graft recipients also have lower CD4 counts at almost
every time point. HAPLO recipients had lower counts com-
pared with SIB recipients up to day þ50, but were compa-
rable thereafter. At 1 year post-transplantation, all 5 groups
had comparable CD4 counts. Median day þ100 serum IgA
levels were lower in all alternative donor groups compared
with the SIB group, especially mmUD recipients (Table 2).Infections
The cumulative incidence of developing CMV antige-
nemia was 58% in the SIB group, 60% in the MUD group, 60%
in the mmUD group, 68% in the UCB group, and 74% in the
HAPLO group (P ¼ .004). The cumulative incidence of EBV
DNAemia >1000 copies  105 cells was 2% in the SIB group,
14% in the MUD group, 12% in the mmUD group, 5% in the
UCB group, and 10% in the HAPLO group (P ¼ .004). Of the
latter group, 6 of 9 patients with EBV DNAemia >1000
copies  105 cells had Hodgkin disease and had relapsed
post-transplantation. Patients with EBV-DNAemia >1000
copies  105 cells were treated with rituximab; no patient
died of lymphoproliferative disease.
The proportion of patients with bacterial infections dur-
ing neutropenia was higher in the alternative donor groups,
which corresponds to a higher proportion of patients with
lethal infections (Table 3). Fungal infections were more
frequent in the alternative donor groups compared with the
SIB group (Table 2).Acute GVHD
The cumulative incidence of acute GVHD (aGVHD) grade
II-IV was signiﬁcantly different across the 5 groups of pa-
tients (P < .001, Fine and Gray): 31% in the SIB group, 21% in
the MUD group, 42% in the mmUD group, 19% in the UCB
group, and 14% in the HAPLO group (Figure 1A). In particular,
a signiﬁcant difference was identiﬁed between the SIB and
HAPLO groups (P < .001) and between the MUD and mmUD
groups (P ¼ .003) (Figure 1A). Sex (P ¼ .80), age (P ¼ .02),
intensity of conditioning (P¼ .40), and disease phase (P¼ .70)
did not impact acute GVHD grade II-IV. The cumulative
incidence of grade III-IV acute GVHDwas 7% in the SIB group,
3% in the MUD group, 9% in the mmUD group, 1% in the UCB
group, and 4% in the HAPLO group (P ¼ .10).UD mmUD UCB HAPLO
3 43 105 92
17 (12-37) 16 (10-29) 23 (14-42)* 18 (11-32)
19 (7-70) 22 (10-97) 24 (8-87) 32 (5-83)*
06 (10-180)* 90 (16-190)* 63 (2-108)* 190 (30-302)
30 (8-262)* 17 (3-113)* 30 (1-300)*
6 44 39 25%
4 9 14 11%
0 60 68 74%
0 57 79* 81%*
07 (8-2822) 426 (2-2834) 372 (2-2672) 576 (11-1578)*
mparisons were made using the Student t test for 2 groups, with SIB as the
roportion of patients with infection on day þ100; both are signiﬁcant at the
P value is < .01 (Fine and Gray method).
Table 3
Primary Causes of Death by Donor Type (n ¼ 459 Patients)
SIB MUD mmUD UCB HAPLO
Number of patients 176 43 43 105 92
Alive, n (%) 92 (52) 20 (47) 18 (42) 38 (36) 52 (57)
Rejection, n (%) 0 (0) 1 (2) 3 (7) 0 (0) 1 (1)
Acute GVHD, n (%) 9 (5) 2 (5) 1 (2) 3 (3) 2 (2)
Chronic GVHD, n (%) 4 (2) 2 (5) 2 (5) 3 (3) 1 (1)
Infections, n (%) 7 (4) 6 (14) 5 (12) 18 (17) 10 (11)
Multiorgan failure,
n (%)
7 (4) 2 (5) 1 (2) 7 (7) 0 (0)
Interstitial
pneumonia. n (%)
4 (2) 0 (0) 3 (7) 2 (2) 1 (1)
Other, n (%) 5 (4) 1 (2) 0 (0) 4 (4) 1 (1)
Relapse, n (%) 48 (26) 9 (21) 10 (23) 30 (29) 24 (26)
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The cumulative incidence of moderate-severe chronic
GVHD (cGVHD) was 29% for the SIB group, 22% for the MUD
group, 19% for the mmUD group, 23% for the UCB group, and
15% for the HAPLO group, with a borderline signiﬁcant trend
(P ¼ .053) toward less cGVHD in the UCB and HAPLO groups
(Figure 1B).Discontinuation of Immunosuppressive Therapy
The number of patients with records evaluable on
day þ180 was 128 in the SIB group, 32 in the MUD group,
30 in the mmUD group, 62 in the UCB group, and 55 in the
HAPLO group. The proportion of patients off CYAclosporine
on day þ180 was 42% in the SIB group, 44% in the MUD
group, 42% in the mmUD group, 56% in the UCB group, and
68% in the HAPLO group (P ¼ .09). The number of evaluable
patients on dayþ365 was 90 in the SIB group, 28 in the MUD
group, 29 in themmUD group, 47 in the UCB group, and 45 in
the HAPLO group, and the responding proportion of patients
off CyA in the 5 groups was 55% in the SIB group, 60% in the
MUD group, 57% in the mmUD group, 79% in the UCB group,
and 81% in the HAPLO group (P < .001).Figure 1. (A) Cumulative incidence of aGVHD. The highest rate for was mismatched un
unrelated cord blood (UCB) and haploidentical family donors (HAPLO). The differe
borderline higher risk for sibling donors.Causes of Death and TRM
Table 3 presents major causes of deaths in the 5 groups.
The cumulative incidence of TRM at 1000 days was 24% for
the SIB group, 33% for the MUD group, 35% for the mmUD
group, 35% for the UCB group, and 18% for the HAPLO group
(P ¼ .10) (Figure 2). For patients in CR1 or CR2 it was 18% in
the SIB group (n¼ 99), 26% in theMUD group (n¼ 25), 32% in
the mmUD group (n ¼ 19), 37% in the UCB group (n ¼ 62),
and 17% in the HAPLO group (n ¼ 39) (P ¼ .06). For patients
with advanced disease, it was 32% in the SIB group (n ¼ 77),
33% in the MUD group (n ¼ 18), 41% in the mmUD group
(n ¼ 24), 33% in the UCB group (n ¼ 43), and 19% in the
HAPLO group (n ¼ 53) (P ¼ .20). Other variables, including
patient age, sex, conditioning regimen, and disease phase,
were not predictive of TRM.Relapse
The cumulative incidence of relapse was 40% in the SIB
group, 23% in the MUD group, 30% in the mmUD group, 30% in
the UCBgroup, and 35% in theHAPLO group (P¼ .89) (Figure 3).
For patients with early disease (CR1 or CR2), it was 36% in the
SIB group, 20% in the MUD group, 15% in the mmUD group,
24% in the UCB group, and 18% in the HAPLO group (P ¼ .09).
For patients with advanced disease (>CR2), the respective
values were 47%, 28%, 42%, 40%, and 47% (P ¼ .60). In multi-
variate analysis, disease phasewas associatedwith a signiﬁcant
increased incidence of relapse (SHR, 2.05; 95% CI, 1.42 to 2.97;
P < .001). When stratiﬁed for myeloablative and RIC regimens,
disease phase remained the sole predictor of relapse.Overall Survival
The actuarial 4-year overall survival was 45% for the SIB
group, 43% for the MUD group, 40% for the mmUD group,
34% for the UCB group, and 52% for the HAPLO group (P¼ .10,
log-rank test) (Figure 4). When stratiﬁed for disease phase,
the 4-year actuarial survival in patients in CR1 or CR2 was
53% for the SIB group, 63% for the MUD group, 52% for the
mmUD group, 33% for the UCB group, and 57% for the HAPLOrelated donors (mmUD), followed by siblings (SIB), matched unrelated (MUD),
nce is signiﬁcant (P < .001). (B) Cumulative incidence of cGVHD, showing a
Figure 4. Actuarial survival of patients stratiﬁed for donor type. Overall there
is no statistically signiﬁcant difference in survival.
Figure 2. Cumulative incidence of TRM. The UCB, mmUD, and MUD show
higher TRM compared with SIB and HAPLO donors; overall the difference is
not signiﬁcant, however.
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values were 30%, 31%, 20%, 27%, and 47% (P ¼ .20).
DFS
The actuarial 4-year DFS of patients was 32% for the SIB
group, 36% for the MUD group, 34% for the mmUD group,
33% for the UCB group, and 43% for the HAPLO group
(P ¼ .20). When stratiﬁed for disease phase, DFS for patients
in CR1 or CR2 was 38% for the SIB group, 35% for the MUD
group, 40% for the mmUD group, 38% for the UCB group, and
60% for the HAPLO group (P ¼ .10); for patients with
advanced disease at transplantation, respective values were
22%, 39%, 18%, 28%, and 32% (P ¼ .60).
Multivariate Analysis
Variables with a P value <.15 were entered into a multi-
variate Cox model. The most signiﬁcant negative predictor of
survival was disease phase, with an HR of 2.4 for patients
with advanced disease versus patients in CR1 or CR2
(Table 4). Other negative predictors were a diagnosis of acute
leukemia versus a chronic disorder (HR, 1.8) and the use of
UCB graft versus a SIB graft (HR, 1.4); age over the median
value of 44 years and female donor/male recipient were
not predictive (Table 4). Variables that did not reach the
0.15 level to be entered into the multivariate model wereFigure 3. Cumulative incidence of relapse. Slightly higher rates are seen for
the SIB and HAPLO groups.donor sex (P ¼ .30), intensity of conditioning regimen
(RIC versus myeloablative) (P ¼ .27), ABO match (P ¼ .25),
year of transplantation (P ¼ .25), time between diagnosis
and transplantation (P ¼ .95), and CMV serostatus pre-
transplantation (P ¼ .30).DISCUSSION
Unmanipulated haploidentical transplants have become
more popular in recent years, supported by encouraging
results reported from several different centers [8-12]. This
is particularly true in Italy, as demonstrated by the EBMT
survey [19], with a rapid increase of HAPLO grafts in the last
years, to more than 35 per 106 inhabitants, compared with
15 per 106 in Germany and<10 per 106 in France [19]. Several
platforms for unmanipulated HAPLO transplantations are
available, including the use of intensive immunosuppression,
including ATG, with granulocyte colony-stimulating factor
(G-CSF)-mobilized blood and marrow [8], G-CSFemobilized
marrow [15], G-CSFemobilized peripheral blood [20], or PT-
CY with unmanipulated marrow or peripheral blood [11,21].
The latter approach may expose patients to an increased
risk of relapse, because cyclophosphamide-induced in vivo
depletion of alloreactive T cells may reduce both GVHD and
the graft-versus-leukemia effect [9,11,22]. Indeed, in a com-
parison of PT-CY haploidentical transplants and UCB grafts
condititioned with a nonmyeloablative regimen, the relapse
rate was higher in the haploidentical transplant recipients,
although survival was similar in both groups, owing to a
greater risk of TRM in UCB recipients [23].Table 4
Multivariate Cox Analysis of Survival
Variable Baseline Comparison HR 95% CI P Value
Disease phase CR1þCR2 Advanced 2.44 1.8-3.2 <.0001
Diagnosis Chronic
disease
Acute
leukemia
1.84 1.3-2.5 .0001
Patient age 44 yr >44 yr 1.21 0.9-1.5 .13
Donor type SIB MUD 1.01 0.6-1.6 .96
SIB mmUD 1.21 0.7-1.8 .40
SIB UCB 1.40 1.0-1.9 .03
SIB HAPLO 0.95 0.6-1.3 .80
Donor/recipient sex Other Female/male 1.14 0.8-1.5 .36
Chronic disease includes lymphoma, myeloﬁbrosis, chronic myelogenous
leukemia, myelodysplastic syndrome, and chronic lymphocytic leukemia).
Acute leukemia includes acute myelogenous leukemia and acute lympho-
blastic leukemia.
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that unmanipulated marrow HAPLO transplants with PT-CY
can compare with conventional transplants from other fam-
ily matched or alternative donors. In a multivariate analysis of
survival, HAPLO and MUD grafts yielded overall survival not
statistically different from SIB grafts, whereas UCB andmmUD
grafts had somewhat inferior outcomes. Advanced disease
phase and a diagnosis of acute leukemia were the other 2
negative predictors of survival, in keeping with large registry
studies demonstrating the impact of disease and stage risk
groups [24].
We were impressed with the relatively low TRM in the
HAPLO group both in patients with leukemia receiving
myeloablative conditioning and in patients with Hodgkin
disease receiving an RIC regimen, conﬁrming our initial
experience [10,12]. Compared with SIB recipients, HAPLO
recipients had similar TRM, whereas UCB and mmUD re-
cipients had higher TRM. One reason for low TRM is rapid
immune recovery; CD4 counts in the HAPLO group were
comparable to those in the SIB group and higher than those
in theMUD,mmUD, and UCB groups on daysþ100 andþ180.
This is not to say that infections were not seen; CMV reac-
tivation in HAPLO grafts was similar to that in the MUD,
mmUD, and UCB grafts and greater than that in the SIB grafts.
The same can be said for early bacterial infections as well.
Mortality due to infection as the primary cause of death
was highest in the UCB group (17%) and lowest in the SIB
group (4%), whereas the MUD (14%), mmUD (12%), and
HAPLO (11%) groups had a similar intermediate risk of lethal
infection.
GVHD remains a signiﬁcant problem in alternative donor
transplants, and in this series we could identify 2 groups of
patients, one with an average 18% cumulative incidence of
developing acute GVHD II-IV and another with an average
risk of 36%. The ﬁrst group included HAPLO, UCB, and MUD
recipients, and the second group comprised SIB and mmUD
recipients. This distribution was conﬁrmed by multivariate
analysis. One may be surprised that SIB grafts carry a high
risk of aGVHD, but we still use cyclosporine/methotrexate for
SIB grafts, with ATG added for MUD, mmUD, and UCB grafts
and PT-CY added for HAPLO grafts. There was also a clear
difference between matched and mismatched UD trans-
plants, with signiﬁcantly more acute GVHD in the mmUD
group. The probability of being off cyclosporine at 1 year was
signiﬁcantly higher in the HAPLO group, conﬁrming the low
rate of aGVHD and cGVHD, using high-dose post-trans-
plantation cyclophosphamide; however, it should be noted
that all HAPLO recipients had unmanipulated bone marrow
as the stem cell source. A recent study of PT-CY in patients
receiving unmanipulated peripheral blood from haploi-
dentical family donors reported encouraging results in terms
of both TRM and survival [21]. Difference between that study
and the present study include a greater use of RIC regimens
(66% of their patients versus 23% of ours) and a higher rate of
extensive cGVHD (38%, compared with 5% of our HAPLO re-
cipients, with bone marrow as the stem cell source). This
ﬁndingmay be relevant for long-term quality of life, showing
that unmanipulated peripheral blood with PT-CY following a
fully myeloablative conditioning regimen should be used
with caution in our opinion.
Relapse remains a signiﬁcant problem in allogeneic stem
cell transplantation [23]. We found a comparable risk of re-
lapse in the 5 different donor groups, with disease phase as
the major predictor of relapse in multivariate analysis. This
also was true when looking at the effect of donor typeseparately, in patients who underwent transplantation with
early or advanced disease. The comparable risk of relapse
in all 5 groups may be related to the fact that we used RIC
regimens in only a minority of patients, and, particularly in
the HAPLO program, only for thosewith Hodgkin disease.We
therefore conﬁrm our previously reported data [12] sug-
gesting that the combination of a myeloablative conditioning
regimen and PT-CY will produce control of the underlying
disease, comparable to other conventional transplants. In
keeping with this observation, relapse as the primary cause
of death did not differ signiﬁcantly across the 5 groups.
There are several limitations to the present retrospective
analysis. First, it was performed in a single center, and our
results remain to be conﬁrmed in a multicenter study with
varying transplantation policies and procedures and GVHD
prophylaxis regimens. Second, it includes both early and
advanced patients with both acute and chronic diseases as
they entered the unit for an allogeneic transplant. Third,
GVHD prophylaxis regimens were different in the 5 groups,
though homogeneous for each donor type. ATG was used
only in the MUD, mmUD, and UCB groups, whereas PT-CY
was used only for in the HAPLO group. The question
whether any of these transplant programs may be applicable
also to other donor types awaits prospective testing, that
is, the same program, including conditioning regimen and
GVHD prophylaxis, tested with different donor types. An
additional criticism may be that UCB was infused intrabone
in this study, in contrast to conventional i.v. infusion: how-
ever in a matched-pair analysis, patients receiving a single
UCB unit infused intrabone showed a trend toward less
relapse and superior DFS compared with patients receiving
double UCB units infused i.v. [25].
A strength of the present study is that is reﬂects real life
in a transplantation unit over the last 6 years, with a high
proportion of patients with leukemias and myelodysplastic
syndromes, including many with advanced disease, often
older than 50 or 60 years, the majority searching for alter-
native donors in the absence of a matched sibling, with little
time to maintain a second remission or a suitable clinical
condition.
In conclusion, we now have different and competing
options for alternative donors for patients who lack an
HLA-identical sibling; the outcome appears to be comparable
using either MUD or HAPLO grafts, also after correcting for
disease phase and diagnosis. Time to identify a suitable
donor remains a crucial issue and has, in our recent experi-
ence, often shifted the choice to the HAPLO donor. The cost of
each procedure, including donor search and stem cell pro-
curement, is an additional issue. A longer follow-up and a
larger number of patients will tell us if unmanipulated
HAPLO grafts can really compete with grafts from other
alternative donors, including MUD, mmUD, or UCB.
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